Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of incretin mimetic medicines for the treatment of Type 2 ...

Good afternoon, and welcome to the Bolt Biotherapeutics Strategic Update Conference Call. At this time, all participants are ...

Q1 2024 Earnings Call Transcript May 18, 2024 Operator: Good afternoon. My name is Jenny, and I will be your operator today ...

One in eight adults (12 percent) say they have ever taken a glucagon-like peptide-1 receptor agonist (GLP-1 RA) and 6 percent ...

Newly released clinical trial data on the GLP-1 agonist drug Wegovy found that weight loss was sustained for up to four years ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive results from the Phase Ib ...

Mizuho analysts are betting the stock of the small biotech Terns Pharmaceuticals Inc. could rally sharply if the company’s ...

Viking Therapeutics (VKTX) stock falls after Roche (RHHBY) posted promising Phase 1 results for its experimental obesity ...

VK2735 is Viking's GLP-1 agonist, and it has achieved strong results in clinical trials. Participants in a phase 2 trial who ...

South San Francisco, California Saturday, May 18, 2024, 09:00 Hrs [IST] ...

The sweet-taste receptor might be the first stop in a metabolic surveillance system for sugar. The receptor is also expressed ...